Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.

Slides:

Advertisements

Similar presentations

A Prospective, Randomized Comparison of Paclitaxel-eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.

Advertisements

The EMERALD Trial Diabetic Substudy. EMERALD Diabetic Analysis To compare myocardial perfusion and infarct sizes in diabetic and non-diabetic patients.

Post-conditioning the human heart to reduce infarct size

Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:

Francesco Burzotta HOTLINE III, ESC Congress 2007 September 4th 2007, Vienna OPTIMIST: the Outcome of Pci for stent-ThrombosIs MultIcentre STudy Institute.

Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.

Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.

Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.

on behalf of the TOTAL Investigators

TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.

STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,

Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.

University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.

SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.

TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.

CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.

Efficacy of high dose atorvaSTATIN loading before primary percutaneous coronary intervention in ST Elevation Myocardial Infarction (STATIN STEMI) Jung-Sun.

Presentation at a Non PCI Facility Requiring Transfer Does NOT Worsen Long-term Prognosis in Patients With STEMI Undergoing Primary Angioplasty. The HORIZONS-AMI.

ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.

One patient, two years, three choices, four PCI ZHAO Peng Cardiology ， the Affiliated Hospital of Medical College of CPAPF, Tianjin, China.

AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.

Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.

SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.

RESEARCH, REDUCE III, X-AMINE ST, COOL-MI Azfar Zaman Freeman Hospital, Newcastle.

UNIVERSITÄT LEIPZIG H E R Z Z E N T R U M Infarct transmurality and infarct size assessed by delayed enhancement magnetic resonance imaging: Association.

CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.

LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,

Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.

DEDICATION Peter Clemmensen, Henning Kelbæk, Anne Kaltoft, Steffen Helqvist, Jens Flensted Lassen, Lene Kløvgaard, Christian J Terkelsen, Hans Henrik Tilsted,

Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.

Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.

Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)

ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.

Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.

Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,

Drug Eluting Balloon in Acute Myocardial Infarction: (PI) On behalf of the DEB-AMI study group (PI) P.R. Stella, MD, PhD 6 month.

The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: ischemic postconditioning during primary.

Impact Of Diabetes Mellitus On The Safety And Effectiveness Of Bivalirudin In Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty:

Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.

Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.

A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.

SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.

End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to

Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE

M-Guard stent in STEMI patients with high thrombus burden lesions Mahmoud Shabestari Baktash Bayani Ali Eshraghi Bahram Shahri Mashhad University.

Total Occlusion Study of Canada (TOSCA-2) Trial

On behalf of J. Belardi, M. Leon, L. Mauri,

Thomas Stiermaier, MD; Suzanne de Waha, MD;

The American College of Cardiology Presented by Dr. Maurits T. Dirksen

Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:

Impact of Platelet Reactivity Following Clopidogrel Administration

Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.

SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Michael.

Presented at TCT 2006.

Impact of Diabetes Mellitus on Long-term Outcomes in the

Patient Examples of CMR Stress Test in Women Patient #1 is a 70-year-old, post-menopausal woman with typical angina and 3 coronary artery disease (CAD)

Maintenance of Long-Term Clinical Benefit with

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.

Infarct Size after Primary Angioplasty Patients With Bivalirudin

Ahmed A. Khattab, MD For the German Cypher Registry Investigators

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

Presentation transcript:

Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Peter Clemmensen, Lene Holmvang, Marek Treiman, Jan S Jensen, Henning Kelbæk Niels Vejlstrup, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Peter Clemmensen, Lene Holmvang, Marek Treiman, Jan S Jensen, Henning Kelbæk, Thomas Engstrøm Department of Cardiology RigshospitaletCopenhagenDenmark

POSTCON Copenhagen University Hospital Presenter Disclosure The authors have no disclosures with regard to the conduct of this study

POSTCON Copenhagen University Hospital Background Zhao et al., 2003

POSTCON Copenhagen University Hospital Background Zhao et al., 2003

POSTCON Copenhagen University Hospital Postconditioning has been suggested to reduce myocardial damage during PPCI in patients with ST- segment elevation myocardial infarction (STEMI) However clinical experience is limited Background

POSTCON Copenhagen University Hospital Conventional treatment coronary artery ReperfusionOccluded Postconditioning Post- conditioning sec30 Balloon inflations - deflations

POSTCON Copenhagen University Hospital STEMI - PPCI Randomization Postconditioning Conventional treatment Continue standard treatment Balloon inflation 30 sec / reperfusion 30 sec Continue standard treatment Postconditioning

POSTCON Copenhagen University Hospital Patients who presented with symptoms and signs of their first STEMI Chest pain for less than 12 hours TIMI 0-I (range 0-III) in the infarct related artery Major inclusion criteria

POSTCON Copenhagen University Hospital Major exclusion criteria History of a previous myocardial infarction Left main stenosis Spontaneous reperfusion before intervention (TIMI II-III) Multivessel disease (any other stenosis > 70%) Cardiogenic shock Stent thrombosis

POSTCON Copenhagen University Hospital Endpoints Primary: Infarct size measured with CMR 3 months after the initial procedure (analysis blinded)

POSTCON Copenhagen University Hospital Endpoints Secondary: Cardiac death after 1 and 15 months Clinical status after 3 months (angina, heart failure) TLR during hospitalization, after 1 and 15 months Re-infarction during hospitalization, after 1 and 15 months LVEF by CMR

POSTCON Copenhagen University Hospital Screened patients 530 Eligible patients 118 Did not meet inclusion criteria TIMI > 1 before PCI - 64 no myocardial infarction - 44 multiple vessel disease - 39 linguistic problems - 28 duration of symptoms >12 hours - 28 cardiogenic shock - 27 did not meet inclusion criteria - 23 unconsciousness - 17 refused to participate - 12 stentthrombosis - 11 vessel unsuitable for postconditioning - 24 no reason reported 2 deaths 30 lost to CMR - 15 logistic problems - 6 claustrophobia - 3 pacemaker implantation - 3 nephropathy - 3 technical difficulties 86 patients for CMR 116 patients for 3-month clinical follow-up Flow Chart

POSTCON Copenhagen University Hospital Mean age (yrs) Male gender (%) Diabetes (%) Hypertension (%) Treatment for hyperlipidemia (%) Current smoker (%) Family history of CAD (%) Previous myocardial infarction (%) Previous PCI (%) Symptom onset to balloon (min) Time to CMR (days) Use of GP IIb/IIIa inhibitor (%) Use of bivalirudin (%) ± ± ± ± p ns Baseline clinical demography Post- conditioning n = 59 Conventional Treatment n = 59

POSTCON Copenhagen University Hospital Mean age (yrs) Male gender (%) Diabetes (%) Hypertension (%) Treatment for hyperlipidemia (%) Current smoker (%) Family history of CAD (%) Previous myocardial infarction (%) Previous PCI (%) Symptom onset to balloon (min) Time to CMR (days) Use of GP IIb/IIIa inhibitor (%) Use of bivalirudin (%) ± ± ± ± p ns Baseline clinical demography Post- conditioning n = 59 Conventional Treatment n = 59

POSTCON Copenhagen University Hospital Mean age (yrs) Male gender (%) Diabetes (%) Hypertension (%) Treatment for hyperlipidemia (%) Current smoker (%) Family history of CAD (%) Previous myocardial infarction (%) Previous PCI (%) Symptom onset to balloon (min) Time to CMR (days) Use of GP IIb/IIIa inhibitor (%) Use of bivalirudin (%) ± ± ± ± p ns Baseline clinical demography Post- conditioning n = 59 Conventional Treatment n = 59

POSTCON Copenhagen University Hospital Mean age (yrs) Male gender (%) Diabetes (%) Hypertension (%) Treatment for hyperlipidemia (%) Current smoker (%) Family history of CAD (%) Previous myocardial infarction (%) Previous PCI (%) Symptom onset to balloon (min) Time to CMR (days) Use of GP IIb/IIIa inhibitor (%) Use of bivalirudin (%) ± ± ± ± p ns Baseline clinical demography Post- conditioning n = 59 Conventional Treatment n = 59

POSTCON Copenhagen University Hospital Baseline angiographic results Number of Diseased vessels (%) 1 Vessel Disease 2 Vessel Disease 3 Vessel Disease Infarct related artery (%) LAD RCA LCX / PDA / PLA/ OM / D TIMI 0-I before procedure Visible thrombus (%) ns p Post- conditioning n = 59 Conventional Treatment n = 59

POSTCON Copenhagen University Hospital Baseline angiographic results Number of Diseased vessels (%) 1 Vessel Disease 2 Vessel Disease 3 Vessel Disease Infarct related artery (%) LAD RCA LCX / PDA / PLA/ OM / D TIMI 0-I before procedure Visible thrombus (%) ns p Post- conditioning n = 59 Conventional Treatment n = 59

POSTCON Copenhagen University Hospital Baseline angiographic results Number of Diseased vessels (%) 1 Vessel Disease 2 Vessel Disease 3 Vessel Disease Infarct related artery (%) LAD RCA LCX / PDA / PLA/ OM / D TIMI 0-I before procedure Visible thrombus (%) ns p Post- conditioning n = 59 Conventional Treatment n = 59

POSTCON Copenhagen University Hospital Baseline angiographic characteristics Number of Diseased vessels (%) 1 Vessel Disease 2 Vessel Disease 3 Vessel Disease Infarct related artery (%) LAD RCA LCX / PDA / PLA/ OM / D TIMI 0-I before procedure Visible thrombus (%) ns p Post- conditioning n = 59 Conventional Treatment n = 59

POSTCON Copenhagen University Hospital Procedural Results Type of stent (%) None BMS DES Number of stents (%) Diameter of final balloon, mm Length of stented segment, mm Max deployment pressure, mmHg Thrombectomy (%) TIMI grade III after procedure (%) ns p Post- conditioning n = 59 Conventional Treatment n = 59

POSTCON Copenhagen University Hospital Procedural Results Type of stent (%) None BMS DES Number of stents (%) Diameter of final balloon, mm Length of stented segment, mm Max deployment pressure, mmHg Thrombectomy (%) TIMI grade III after procedure (%) ns p Post- conditioning n = 59 Conventional Treatment n = 59

POSTCON Copenhagen University Hospital Procedural Results Type of stent (%) None BMS DES Number of stents (%) Diameter of final balloon, mm Length of stented segment, mm Max deployment pressure, mmHg Thrombectomy (%) TIMI grade III after procedure (%) ns p Post- conditioning n = 59 Conventional Treatment n = 59

POSTCON Copenhagen University Hospital CMR – late enhancement

POSTCON Copenhagen University Hospital CMR – late enhancement = Infarct mass = LV mass Infarct (%) = Infarct mass / LV mass

POSTCON Copenhagen University Hospital CMR – The wavefront phenomenon Myocardium at risk Final infarct 40 minutes 3 hours96 hours

POSTCON Copenhagen University Hospital CMR – Area At Risk Ortiz-Pérez et al., Apex Basis = Infarct = None-infarct AAR-ESA = Infarct / (none-infarct + Infarct)

POSTCON Copenhagen University Hospital p=0.987 p=0.037 p=0.007 Results - CMR

POSTCON Copenhagen University Hospital Results - CMR Lønborg et al., 2010

POSTCON Copenhagen University Hospital Infarct size Results - CMR

POSTCON Copenhagen University Hospital Infarct size Results - CMR p= interaction test

POSTCON Copenhagen University Hospital p=0.705 Infarct size - interaction test Results - CMR AAR = Area At Risk

POSTCON Copenhagen University Hospital Heart failure p=0.048 Angina pectoris p=0.362 Clinical outcome at 3 months 7

POSTCON Copenhagen University Hospital Myocardial infarction, n (%) STEMI NSTEMI Stent thrombosis, n (%) Pacemaker, n (%) PCI on target vessel, n (%) CABG, n (%) Death, n (%) 0 (0) 3 (5) 0 (0) 1 (2) 0 (0) 2 (3) 0 (0) 1 (2) 2 (3) 1 (2) 0 (0) ns p Post- conditioning n = 59 Conventional Treatment n = 59 Clinical outcome at 3 months

POSTCON Copenhagen University Hospital Postconditioning reduces infarct size in patients with STEMI Postconditioning improves functional class in patients with STEMI The treatment is independently effective for all Areas At Risk Postconditioning should be tested in larger clinical trials Conclusion